Is there any predictor for clinical outcome in EGFR mutant NSCLC patients treated with EGFR TKIs?
Lee JY, Lim SH, Kim M, Kim S, Jung HA, Chang WJ, Choi MK, Hong JY, Lee SJ, Sun JM, Ahn JS, Park K, Ahn MJ.
Lee JY, et al. Among authors: choi mk.
Cancer Chemother Pharmacol. 2014 May;73(5):1063-70. doi: 10.1007/s00280-014-2442-8. Epub 2014 Mar 25.
Cancer Chemother Pharmacol. 2014.
PMID: 24663503